NCT06263673

Anti-Diabetic Medications to Fight PD and LBD

Anti-Diabetic Medications to Fight Parkinson's Disease and Lewy Body Dementia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 45 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.

Conditions

• Lewy Body Dementia
• Parkinson Disease

Interventions

Type	Name	Description
DRUG	Sitagliptin	100 mg once daily, oral
DRUG	Dapagliflozin	10 mg once daily, oral
DRUG	Placebo	Once daily, oral. Looks similar to the study drug, but it contains no active ingredient.

Timeline

• Start date: 2024-05-07
• Primary completion: 2025-01-08
• Completion: 2025-01-08
• First posted: 2024-02-16
• Last updated: 2026-01-28
• Results posted: 2026-01-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study